Vor Biopharma (VOR)
Develops licensed telitacicept for autoimmune diseases outside Greater China.
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 89.74% | 48.63M shares | |
|---|---|---|---|
| 105 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.26% | 142.6K shares | |
| 7 holders · as of Apr 9, 2026 | |||
| Strategic holders | 16.61% | 9.00M shares | |
| 3 holders · as of May 15, 2026 | |||
| Adds to | 106.61% | ||
54.19M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (59.16M in the company's Sep 22, 2026 report, 54.19M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 106.61%; nothing is left for Other.
13F, as of Jun 30, 2026
105 holders · 48.63M shares · 41 new positions · 76 increased · 19 reduced · 17 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 5.67M | 10.47% | 0 | Aug 14, 2026 |
| FMR LLC | 4.93M | 9.10% | +3.39M | Aug 13, 2026 |
| FCPM Iii Services B.V. | 4.12M | 7.60% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 3.47M | 6.40% | +2.67M | Aug 7, 2026 |
| VR Adviser, LLC | 3.04M | 5.61% | 0 | Aug 14, 2026 |
| State Street Corp | 2.62M | 4.83% | +1.50M | Aug 7, 2026 |
| Frazier Life Sciences Management, L.P. | 2.54M | 4.69% | 0 | Aug 14, 2026 |
| Ra Capital Management, L.P. | 2.40M | 4.43% | −3.00M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Rajeev Shahincl. RA Capital Healthcare Fund, L.P., RA Capital Management, L.P. +1 more | 19.90% | 12.94M | 13D | Jul 21, 2026 |
| Reprogrammed Interchange LLCincl. Reid Hoffman | 18.60% | 1.28M | 13D | Oct 16, 2025 |
| ForGrowth III PA B.V.incl. Forbion Growth Opportunities Fund III Cooperatief U.A., Forbion Growth III Management B.V. | 9.99% | 10.24M | 13D | Dec 23, 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 9.90% | 5.08M | 13G | May 15, 2026 |
| Verve Capital Limited | 9.30% | 5.00M | 13G | May 15, 2026 |
| Frazier Life Sciences Public Fund, L.P. | 5.80% | 2.26M | 13G | Dec 19, 2025 |
| BlackRock, Inc. | 5.70% | 3.10M | 13G | Jul 30, 2026 |
| TCG Crossover GP II, LLC | 5.20% | 2.84M | 13G | Apr 1, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 16, 2026 | Ra Capital Management, L.P.10 percent owner | Sale | 213 | $19.75 | 4,501,882 |
| Apr 22, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Sale | 165,150 | $15.77 | 2,402,095 |
| Apr 20, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Sale | 171,963 | $15.77 | 2,567,245 |
| Apr 17, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Sale | 458,411 | $16.28 | 2,739,208 |
| Apr 15, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Sale | 53,644 | $16.01 | 3,197,619 |
| Apr 14, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Sale | 153,735 | $15.97 | 3,251,263 |
| Apr 13, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Sale | 530,610 | $16.15 | 3,404,998 |
| Apr 10, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Sale | 828 | $15.75 | 3,935,608 |
| Apr 9, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Sale | 135,201 | $16.59 | 3,936,436 |
| Apr 8, 2026 | Ra Capital Management, L.P.director, 10 percent owner: | Sale · 2 lots | 484,104 | $16.48 | 4,071,637 |
House and Senate disclosures
Not reported.